rtmark
LearnBonds.com

Why’s Clover Health Stock Rising and Should You Buy Now

clover health

Clover Health stock rose over 20% yesterday and was trading higher in US premarket trading today. Should you buy the stock?

The Center for Medicare and Medicaid Innovation has selected Clover Health as one of 53 companies to participate in Medicare and Medicaid’s Global and Professional Direct Contracting Model. The stock rose sharply towards the latter part of the day after the news came out.

Clover Health

Clover Health went public through a reverse merger with Social Capital Hedosophia Holdings III (IPOC). IPOC was the third SPAC from Chamath Palihapitiya. He has already taken Opendoor and Virgin Galactic public with two of his SPACs. His Social Capital Hedosophia Holdings V (IPOV) is set to merge with fintech company SoFi.

Tow of his SPACs, Social Capital Hedosophia Holdings IV (IPOD). And Social Capital Hedosophia Holdings VI (IPOF) is still hunting for targets. Palihapitiya, who some see as the “king of SPACs” has reserved all the tickers from IPOG to IPOZ in alphabetical order.

Hindenburg Research allegations

Clover Health stock had fallen to a 52-week low of $6.31. The stock has been on a losing spree after short-seller Hindenburg Research accused the company of fraud and hiding material facts. Hindenburg, which has previously targeted companies like Nikola and Kandi Technologies also, also accused Palihapitiya and questioned his due diligence in selecting the merger target.

In its allegation, Hindenburg Research said “Clover has not disclosed that its business model and its software offering, called the Clover Assistant, are under active investigation by the Department of Justice (DOJ), which is investigating at least 12 issues ranging from kickbacks to marketing practices to undisclosed third-party deals, according to a Civil Investigative Demand.”

Clover Health’s response

It also accused the company of falsely promoting its subsidiary “Seek Insurance” as independent while it is linked to Clover Health. It also said that “Multiple former employees explained that much of Clover’s sales are fueled by a major undisclosed relationship between Clover and an outside brokerage firm controlled by Clover’s Head of Sales, Hiram Bermudez.”

Nikola

Meanwhile, Clover Health also responded to the allegations and added that the DOJ investigation was not material enough to disclose. Nonetheless, the SEC launched an investigation into the company which typically happens in such cases.

To be sure, Hindenburg Research has built a good reputation and its allegations against Nikola led to the exit of the company’s founder Trevor Milton and General Motors scaled back on its partnership with the company.

Is Clover Health a good stock

Clover Health has a market capitalization of around $3.6 billion. While announcing the merger Palihapitiya had forecast that the company would post revenues of $880 million in 2021. This would mean a price to sales multiple of around 4.5x. The company is nearly doubling its revenues every year so that valuation multiples look attractive. The stock is a good way to play the healthcare industry.

How to buy Clover Health stock?

You can invest in Clover stock through any of the reputed online stockbrokers. An alternative approach to investing in the healthcare sector could be to invest in ETFs that invest in healthcare stocks.

Through a healthcare ETF, you can diversify your risks across many companies instead of just investing in a few companies.

You many also chose from ETFs that invest in IPOs of newly listed companies. The Renaissance IPO ETF has outperformed the S&P 500 by a wide margin since the beginning of 2020 reflecting the strong performance of IPOs.

By investing in an ETF, one gets returns that are linked to the underlying index after accounting for the fees and other transaction costs. There is also a guide on how to trade in ETFs.

Trusted & Regulated Stock & CFD Brokers

Rating

What we like

  • 0% Fees on Stocks
  • 5000+ Stocks, ETFs and other Markets
  • Accepts Paypal Deposits

Min Deposit

$200

Charge per Trade

Zero Commission on real stocks

Rating

64 traders signed up today

Visit Now

67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.

Available Assets

  • Total Number of Stocks & Shares5000+
  • US Stocks
  • German Stocks
  • UK Stocks
  • European
  • ETF Stocks
  • IPO
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 Zero Commission
  • NASDAQ Zero Commission
  • DAX Zero Commission
  • Facebook Zero Commission
  • Alphabet Zero Commission
  • Tesla Zero Commission
  • Apple Zero Commission
  • Microsoft Zero Commission

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account
  • Paypall
  • Skrill
  • Neteller

What we like

  • 0% Commission
  • Trade Stocks Via CFDs
  • Authorized & regulated by the FCA

Min Deposit

$100

Charge per Trade

Zero Commission

Rating

Visit Now

76.4% of retail investor accounts lose money when trading CFDs with this provider.

Available Assets

  • Total Number of Stocks & Shares+2000
  • US Stocks
  • German Stocks
  • UK Stocks
  • European
  • ETF Stocks
  • IPO
  • Funds
  • Bonds
  • Options
  • Future
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 Zero Commission
  • NASDAQ Zero Commission
  • Dax Zero Commission
  • Facebook Zero Commission
  • Alphabet Zero Commission
  • Tesla Zero Commission
  • Apple Zero Commission
  • Microsoft Zero Commission

Deposit Method

  • Wire transfer
  • Credit Cards
  • Bank Account
  • Paypal
  • Skrill
Users should remember that all trading carries risks and users should only invest in regulated firms. Views expressed are those of the writers only. Past performance is no guarantee of future results. The opinions expressed in this Site do not constitute investment advice and independent financial advice should be sought where appropriate. This website is free for you to use but we may receive commission from the companies we feature on this site.

Mohit Oberoi is a freelance finance writer based in India. he has completed his MBA with finance as majors and also holds a CFA charter. He has over 13 years of experience in financial markets. He has been writing extensively on global markets for the last six years and has written over 6,500 articles. He mainly covers metals, electric vehicles, asset managers, and other macroeconomic news. He also loves writing on personal finance and topics related to valuation.